Role Of Myo-Inositol Supplementation in prevention of Gestational Diabetes Mellitus in parturient women at risk.

Anam Mumtaz; Ainy; Musarrat Batool; Shirza  Sharafat Ali

Anam Mumtaz PIMS
Ainy Senior Registrar MCH Centre, Unit 1,Pakistan Institute of Medical Sciences,Islamabad.
Musarrat Batool Assistant Professor,MCH Centre, Unit 1Pakistan Institute of Medical Sciences Islamabad
Shirza Sharafat Ali Senior Registrar MCH Center, Unit I Pakistan Institute of Medical Sciences Islamabad

Keywords: Gestational diabetes, Myo-Inositol supplementation

Abstract

Introduction: Several inositol isomers and in particular Myo-inositol (MI) is shown to be efficient in lowering post-prandial blood glucose. Myo-inositol can be found in pulses, nuts, and fruits (in particular citrus fruits). Initial evidence shows reduction in gestational diabetes by up to 60% as the effect of Myo-inositol supplementation. This study aimed to assess frequency of Gestational Diabetes Mellitus in parturient women at risk after supplementation of Myo-Inositol as compared to placebo.
Methodology: This Randomized Controlled trial was conducted in the Outpatient Department of Obstetrics and Gynecology, PIMS, Islamabad from 15th July 2020 to 14th January 2021. A total 120 pregnant women irrespective of parity in first trimester having: 1 or more first-degree relative diagnosed with diabetes mellitus, who were overweight (BMI >25 kg/m2) or Obese (BMI >30 kg/m2) at their first antenatal visit were selected. Women with already diagnosed with Diabetes Mellitus were excluded. Starting from the end of first trimester or start of second trimester (12-15 weeks of gestation) the intervention group was supplemented with 2g Myo-Inositol and 200 mcg Folic acid twice daily as compared to placebo which was given only 200 mcg Folic acid twice daily. Between 24-48 weeks, they were tested for 75gm 2 hour OGTT. Ethical clearance was taken and written informed consent was administered.
Results: The mean age of women in interventional group was 27.78 ± 4.07 years and in placebo group was 28.88 ± 4.19 years. The mean gestational age was 9.33 ± 1.90 weeks in intervention and 9.52 ± 1.85 weeks in the placebo group. In this study, the frequency of Gestational Diabetes Mellitus in parturient women at risk after supplementation of Myo-Inositol was 16.67% as compared to 36.67% in placebo (p-value, 0.01).
Conclusion: Myo-Inositol supplementation reduces the rate of development of GDM in pregnant women having known risk factors.